Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Sprott Uranium Miners ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Sprott Uranium Miners ETF trades at $41.85 (market cap $1.73B). The key difference: Sprott Uranium Miners ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Sprott Uranium Miners ETF for 62 Days on average.
| MRVI | URNM | |
|---|---|---|
Market Cap | $977.37M | $1.73B |
Volume | 2,742,564 | 1,087,852 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $9.00 | $83.99 |
52-Week Low | $2.83 | $42.42 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
URNM (Sprott Uranium Miners ETF) trades at $44.51, down 1.44% today amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages indicating bearish momentum. Recent news highlights uranium's strong fundamentals, with spot prices rising 21.25% over the past year according to Sprott Asset Management (ETF Trends, September 16, 2026). The fund provides concentrated exposure to uranium miners tracking the VettaFi Global Uranium Mining Index.
Long-term outlook remains positive due to nuclear energy expansion and AI power demand, but near-term technical weakness suggests caution. Key risks include uranium price volatility and regulatory uncertainty, while catalysts include government nuclear investments and growing electricity demands from data centers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
